Eikon Therapeutics, Inc. Common Stock News

Latest Eikon Therapeutics, Inc. Common Stock Stock News & EIKN Headlines

Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates

4 days ago | globenewswire.com

Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029

9 days ago | marketbeat.com

Eikon Therapeutics to Participate in Multiple Investor Conferences in November

14 days ago | globenewswire.com

Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress

21 days ago | globenewswire.com

Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress

a month ago | globenewswire.com

Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer

a month ago | globenewswire.com

Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer

2 months ago | globenewswire.com

Eikon Therapeutics to Participate in Investor Conferences in September 2026

3 months ago | globenewswire.com

Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004

3 months ago | marketbeat.com

Eikon Therapeutics, Inc. (EIKN) Discusses Advances in PARP1 Biology and Next-Generation PARP Inhibitors in Oncology Transcript

3 months ago | seekingalpha.com

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

Market Closed

EIKN

Eikon Therapeutics, Inc. Common Stock

$ 5.98

-0.99%

Last 24H

Trading with leverage comes with a high risk and may not be suitable for everyone.

Portfolio

Updated 2 days ago

Top

Gainers

Losers

Symbol

Last Price

24H CNG

Eikon Therapeutics, Inc. Common Stock News

Latest Eikon Therapeutics, Inc. Common Stock Stock News & EIKN Headlines

Download App

People Also Watch

Explore our Tools